The Nuts and Bolts of Immunoglobulin Treatment for Antibody Deficiency
- PMID: 27836057
- DOI: 10.1016/j.jaip.2016.09.011
The Nuts and Bolts of Immunoglobulin Treatment for Antibody Deficiency
Abstract
Immunoglobulin therapy is a key element in the management of most patients with primary immunodeficiency disease. Allergist/immunologists should be familiar with the appropriate evaluation of candidates for immunoglobulin, the characteristics of immunoglobulin products, and how to use them to provide the best care to their patients. Available immunoglobulin products appear to be equally efficacious, but they are not interchangeable. Minimizing the risk of serious adverse events and controlling minor side effects is important to ideal patient care. Immunoglobulin may be administered intravenously or subcutaneously. Individualizing the choice of immunoglobulin product, mode of administration, and site of care can optimize the clinical outcome and minimize the burden of care.
Keywords: Antibody deficiency; Immunodeficiency; Immunoglobulin replacement.
Copyright © 2016 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Immunoglobulin Replacement Therapy for Primary Immunodeficiency.Immunol Allergy Clin North Am. 2015 Nov;35(4):713-30. doi: 10.1016/j.iac.2015.07.006. Epub 2015 Sep 4. Immunol Allergy Clin North Am. 2015. PMID: 26454315 Review.
-
Immunoglobulin replacement therapy for primary immunodeficiencies.Immunotherapy. 2014;6(7):853-69. doi: 10.2217/imt.14.54. Immunotherapy. 2014. PMID: 25290417 Review.
-
Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders.BioDrugs. 2014 Aug;28(4):411-20. doi: 10.1007/s40259-014-0104-3. BioDrugs. 2014. PMID: 24925799 Review.
-
Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.Immunotherapy. 2016 Oct;8(10):1175-86. doi: 10.2217/imt-2016-0066. Epub 2016 Jul 28. Immunotherapy. 2016. PMID: 27468136 Clinical Trial.
-
Switching immunoglobulin products, what are the implications? Result of 2018 census of immunology centres.Clin Med (Lond). 2019 May;19(3):201-204. doi: 10.7861/clinmedicine.19-3-201. Clin Med (Lond). 2019. PMID: 31092511 Free PMC article. Review.
Cited by
-
Differential immunomodulation of T-cells by immunoglobulin replacement therapy in primary and secondary antibody deficiency.PLoS One. 2019 Oct 15;14(10):e0223861. doi: 10.1371/journal.pone.0223861. eCollection 2019. PLoS One. 2019. PMID: 31613907 Free PMC article.
-
Primary Immunodeficiency: New Insights and Practical Clinical Approaches.J Allergy Clin Immunol Pract. 2016 Nov-Dec;4(6):1109-1110. doi: 10.1016/j.jaip.2016.10.003. J Allergy Clin Immunol Pract. 2016. PMID: 27836060 Free PMC article. No abstract available.
-
Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.J Allergy Clin Immunol Pract. 2020 Jan;8(1):283-291.e1. doi: 10.1016/j.jaip.2019.08.012. Epub 2019 Aug 17. J Allergy Clin Immunol Pract. 2020. PMID: 31430592 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources